Keywords: Type 2 diabetes, DPP-IV inhibitors, Pioglitazone, Victoza, Byetta, Januvia

Type 2 diabetes agents - DPP-IV inhibitors - will be main beneficiaries of pioglitazone problems

Article | 01 August 2011

Print This

Given the suspension of use in France and Germany and ongoing deliberations at the US Food and and Drug Administration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in